InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Appoints Veteran of Media Industry as Chief Content, Engagement Officer
March 8, 2023
Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, has announced a new chief content and engagement officer. Maureen Connolly, an award-winning content strategic and audience builder, will step into the position. According to the announcement, Connolly has 20-plus years of experience in the health, […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Retains Top Banking Firm to Support Growth, Revenue-Generating Strategy
March 3, 2023
Aditxt Inc. (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, announced that it is working with Riverside Management Group LLC, a merchant banking firm providing investment banking advisory services; RMG will be supporting Aditxt’s strategic growth and revenue generating plans for its subsidiary Pearsanta Inc., […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Forms US-Based Subsidiary with Focus to Expand Innovation Platforms
February 14, 2023
Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced the formation of a U.S.-based wholly owned subsidiary, Pearsanta Inc. The move intends to accelerate the expansion of Aditxt’s second program, AditxtScore(TM), through future strategic revenue and growth-oriented transactions. According to the update, […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Reaches Pivotal Milestone to Advance ADI (TM) Technology
January 20, 2023
Aditxt (NASDAQ: ADTX) recently announced the formation of a U.S.-based wholly owned subsidiary, Adimune Inc., and appointed Joachim-Friedrich Kapp, MD, Ph.D, a 30-year veteran of the pharmaceutical industry, as its chairman and CEO. “Dr. Kapp will be tasked with leading and developing the ADI(TM) immune modulation technology and ADI(TM)-100, Aditxt’s unique and potent antigen-specific immunotherapeutic […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Dedicated to New Era of Precision Medicine
January 11, 2023
Aditxt (NASDAQ: ADTX), a biotech innovation company, is developing and commercializing technologies with a focus on monitoring and modulating, mapping and reprogramming the immune system, designing technologies to provide a personalized immune profile. “In late October 2022, Aditxt announced the creation of its Adimune(TM) program. At the same time, Aditxt announced that Adimune initiated the […]
Aditxt, Inc. (NASDAQ: ADTX) Bolsters Goal to Conduct First-In-Human Clinical Trial Evaluating ADI(TM) Tech with Formation of Adimune, Inc. Subsidiary; Appoints Industry Veteran as Subsidiary Chairman and CEO
January 10, 2023
Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, on January 3, 2023 announced the formation of a U.S.-based wholly owned subsidiary, Adimune, Inc. (“Adimune(TM)”). The company also announced the appointment of Dr. Joachim-Friedrich Kapp, M.D., Ph.D., as the CEO of Adimune(TM) and […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Forms Subsidiary with Focus on Immune Modulation Therapies
January 3, 2023
Aditxt (NASDAQ: ADTX) is a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system. The company today announced the formation of a U.S.-based subsidiary Adimune Inc. (“Adimune(TM)”) and its plans towards submission of a clinical trial application (“CTA”) for its immunotherapeutic technology drug candidate, ADI(TM)-100. The CTA […]
Aditxt Inc. (NASDAQ: ADTX) Announces Goal of First-in-Human Trials for Drug Candidate ADI(TM)-100 with a Focus on Psoriasis
December 28, 2022
Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, is focused on mapping and reprogramming the immune system, designing technologies to provide a personalized immune profile. These technologies are being developed to retrain the immune system to induce tolerance, to address, among other […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Featured in Equity Research Reports
November 28, 2022
Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, was featured in recent equity research reports published by H.C. Wainwright & Co. Titled “Personalizing Precision Immunological Therapy; Initiating at Buy and $4 PT” and “3Q22 Financial Results Reported; Reiterate Buy,” the publications discuss […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces Key Milestone in Advancing Adimune(TM) Program
October 21, 2022
Aditxt (NASDAQ: ADTX) is a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system. The company today announced that its program Adimune(TM) has initiated the GMP manufacturing of drug candidate ADI(TM)-100 as a key milestone toward its goal to begin first-in-human trials during the second half of […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces Publication of Innovative Mathematical Model
October 12, 2022
Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced publication of a mathematical model for predicting the durability and rate of decay of neutralizing antibodies to SARS-CoV-2 in a peer-reviewed research paper in the Journal of Theoretical Biology. The publication, titled […]
InvestorNewsBreaks – Aditxt Inc.’s (NASDAQ: ADTX) AditxtScore(TM) Featured in FedEx Video Presentation
October 7, 2022
Aditxt (NASDAQ: ADTX), a biotech innovation company, has announced that its AditxtScore(TM) is featured by FedEx in a video presentation that showcases the various ways in which both companies are playing critical roles in a challenging environment that includes the nation’s response to COVID-19. In the clip, the Aditxt team provides a virtual tour of […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements
September 29, 2022
Aditxt (NASDAQ: ADTX) is a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system. The company today announced its receipt of confirmation from the Nasdaq Stock Market LLC Hearing Panel that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Issues Corporate Update Following Reverse Stock Split, Closing of $20M Public Offering
September 27, 2022
Aditxt (NASDAQ: ADTX) is a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system. The company today provided shareholders with a corporate update following the completion of a reverse stock split and closing of a previously announced $20 million public offering. “Aditxt’s key to success is multifaceted and tied […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Closes on Recently Announced $20M Public Offering
September 21, 2022
Aditxt Inc. (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, has closed on its recent public offering. The offering was comprised of 3,333,333 shares of common stock or common stock equivalents; the offering also included warrants to purchase up to 3,333,333 shares of common stock. The […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Releases Pricing of Public Offering
September 16, 2022
Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt”), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, has released the pricing of its public offering. The offering consists of 3,333,333 shares of its common stock (or common stock equivalents in lieu thereof) along with warrants to purchase up to 3,333,333 additional shares […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Looking to Solve Medical Challenge in Immune Responses
August 12, 2022
Aditxt (NASDAQ: ADTX) has sought to address a medical conundrum: approximately 50% of all transplanted organs are rejected by the host’s body within 10-12 years despite a wide array of medical innovations in recent years. This highlights the critical need for a practical, cost-effective solution to harmful immune responses. Aditxt is looking to solve this […]
Aditxt Inc. (NASDAQ: ADTX) Seeks to Address Variability of Immune Responses
August 2, 2022
Biotech innovation company, Aditxt, Inc (“Aditxt” or the “Company”) is developing and commercializing technologies focused on monitoring and reprogramming the immune system Their ground-breaking ADi(TM) immune reprogramming platform will be initially directed towards the treatment of psoriasis, type 1 diabetes and skin allografting The Company has also recently begun to commercialize their AditxtScore(TM) proprietary immune […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Featured in Bell2Bell Podcast
Aditxt (NASDAQ: ADTX) was featured in the Bell2Bell Podcast, a part of IBN’s (InvestorBrandNetwork) sustained effort to provide specialized content distribution via widespread syndication channels. Amro Albanna, co-founder, chairman and CEO of Aditxt, joined the latest episode to provide an overview of the company and discuss its business model. “We are a biotech innovation company, […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Equipping Physicians, Individuals with Comprehensive Immune System Views
July 14, 2022
Aditxt (NASDAQ: ADTX) provides the AditxtScore(TM), a proprietary immune mapping technology designed to provide a personalized profile of the immune system. “Licensed from Stanford University, AditxtScore(TM) for COVID-19 is Aditxt’s first commercial product. It enables patients to know the level of protection that an immune response to the SARS-CoV-2 virus or vaccination confers them…The results […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Moves One Step Closer to In-Human Trials with Completion of Preclinical Toxicity Study
July 8, 2022
Aditxt Inc. (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system, has successfully completed a toxicology study evaluating Adimune(TM), its proprietary therapeutic program. The study indicates the safety profile of ADI(TM)-100, ADTX’s immunotherapeutic technology drug, which is designed to treat the rejection of transplanted organs, skin allografting, […]
InvestorNewsBreaks – Aditxt Inc.’s (NASDAQ: ADTX) AditxtScore(TM) Helping Individuals Make More Informed Decisions
July 1, 2022
Aditxt (NASDAQ: ADTX) recently partnered with Premier Medical Laboratory Services to provide individuals with personalized information regarding their immune system via the AditxtScore(TM). A recent article reads: “The AditxtScore can be used to provide those tested with important answers to questions like: Are antibodies present? How are these antibodies present – vaccine or natural immune […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Pursuing Strategy Against COVID-19, Immune System-Related Maladies
June 28, 2022
Aditxt (NASDAQ: ADTX) is focused on developing and commercializing technologies to monitor and reprogram the immune system with the ultimate goal of improving patient outcomes for a variety of conditions. “Aditxt is joining the fight against the pandemic while pursuing a larger strategy against immune system-related maladies ranging from seasonal allergies to organ transplant rejection,” […]
Aditxt Inc. (NASDAQ: ADTX) Authorizes New Channel Partner to Offer AditxtScore(TM) Amid Rising COVID-19 Cases and Possible Fall/Winter Waves
Aditxt, Inc. is a is a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system. The Company’s product AditxtScore(TM) is a proprietary immune mapping technology designed to provide a personalized profile of the immune system; AditxtScore(TM) for COVID-19 is the Aditxt’s first commercial product Aditxt recently announced it had […]
Hope of Herd Immunity Dwindles Alongside Federal COVID-19 Budget and Supplies; Aditxt Inc. (NASDAQ: ADTX) and AditxtScore(TM) Could Create Map to COVID-19 Immune Responses
June 24, 2022
Two years after a vaccine was made available for COVID-19, fewer than 70% of Americans have been vaccinated The AditxtScore(TM) can provide the necessary answers to individualized immune response questions and direct on the best course of treatment for the individual – not the herd No additional funding for COVID-19 relief has been approved by […]
InvestorNewsBreaks – Aditxt Inc.’s (NASDAQ: ADTX) AditxtScore(TM) Added to PMLS Menu of Testing Services
June 14, 2022
Premier Medical Laboratory Services (“PMLS”), a nation-leading advanced medical diagnostics lab, today announced that it has added Aditxt’s (NASDAQ: ADTX) AditxtScore(TM) to its menu of testing services. AditxtScore provides more clarity regarding a patient’s individual immunity profile and allows patients to know their level of protection that an immune response to the virus or vaccination […]
Aditxt Inc.’s (NASDAQ: ADTX) AditxtScore(TM) Platform Provides Consumers and Physicians with Data Needed to Make Informed Health Decisions on COVID-19
Aditxt is a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system. The company’s AditxtScore(TM) for COVID-19 generates an AditxtScore(TM), which offers a detailed profile of a person’s immune response for SARS-CoV-2, allowing consumers and their physicians to understand, manage, and monitor their level of immune response to the […]
New Spike in COVID Infections, 1M+ Death Toll, Underscore Potential Value of Aditxt Inc.’s (NASDAQ: ADTX) Immune Monitoring Technologies
June 10, 2022
Biotech innovation company Aditxt, Inc. is a Richmond, VA based company focused on developing and commercializing technologies to monitor and reprogram the immune system with the ultimate goal of improving patient outcomes for a variety of conditions ranging from seasonal allergies to organ transplant rejection Aditxt’s first commercial product, AditxtScore(TM), helps patients obtain data relating […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Engages IBN for Corporate Communications Expertise
June 9, 2022
Aditxt (NASDAQ: ADTX), a biotech innovation company, today announced that it has selected the corporate communications expertise of IBN (“InvestorBrandNetwork”), a multifaceted financial news and publishing company for private and public entities. As part of the relationship, IBN will leverage its investor based distribution network of 5,000+ key syndication outlets, various newsletters, social media channels, […]
InvestorNewsBreaks – Aditxt Inc.’s (NASDAQ: ADTX) Immune Monitoring Platform ‘Is the Right Technology at the Right Time’
June 6, 2022
Aditxt (NASDAQ: ADTX) recently entered into a multi-year partnership with Guthy-Renker LLC- affiliated GRS. The partnership focuses on building awareness and visibility among consumers and health care providers for the proprietary AditxtScore(TM) Immune Monitoring Platform. “AditxtScore is the right technology at the right time. Our first application, AditxtScore for COVID-19, delivers timely reports on vulnerability […]
InvestorNewsBreaks – Why Aditxt Inc. (NASDAQ: ADTX) Is ‘One to Watch’
May 27, 2022
Aditxt (NASDAQ: ADTX) is a biotech company commercializing new innovations. The company’s first commercial product, AditxtScore(TM), is an immune mapping technology designed to provide a personalized, comprehensive profile of an individual’s immune system. “The company’s first commercial application of the platform, AditxtScore(TM) for COVID-19, delivers timely reports on vulnerability and immune status relating to SARS-CoV-2 […]
Aditxt Inc. (NASDAQ: ADTX) Planning Nationwide Rollout of its AditxtScore(TM) Immune Monitoring Platform
May 23, 2022
Aditxt recently entered a multi-year partnership with GRS for the promotion of its proprietary AditxtScore Immune Monitoring Platform Aditxt plans to roll out the monitoring platform to medical offices, pharmacies, laboratories, and employers across the country, with promotion through nationwide television commercials AditxtScore(TM) monitors the current immune response not genetic sequencing Continuing research into COVID-19 […]
Aditxt Inc. (NASDAQ: ADTX) Is ‘One to Watch’
May 16, 2022
Aditxt is commercializing new innovations with focus on mapping and reprogramming the immune system Aditxt is actively adding distribution channel partners for AditxtScore(TM) throughout the U.S. and globally The company aims to expand reimbursement coverage for AditxtScore(TM) for COVID-19 from private insurance and public payers while developing and commercializing tests for other indications Aditxt intends […]
IBN (InvestorBrandNetwork) Announces Latest Episode of The Bell2Bell Podcast featuring Amro Albanna, CEO of Aditxt, Inc.
August 2, 2022
LOS ANGELES, Aug. 02, 2022 (GLOBE NEWSWIRE) — via InvestorWire – IBN (InvestorBrandNetwork), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The Bell2Bell Podcast delivers informative updates […]
Aditxt Engages IBN (InvestorBrandNetwork) To Bolster Its Corporate Communications Efforts
June 9, 2022
LOS ANGELES, June 09, 2022 (GLOBE NEWSWIRE) — via InvestorWire – Aditxt, Inc. (“Aditxt” or “the Company”) (NASDAQ: ADTX), a biotech innovation company, today announces it has selected the corporate communications expertise of IBN, a multifaceted financial news and publishing company for private and public entities. Aditxt is developing and commercializing new innovations aimed at monitoring and reprogramming the […]
Bad Crypto Podcast and RAILGUN Form Partnership
November 3, 2021
NEW YORK, Nov. 03, 2021 (GLOBE NEWSWIRE) — via InvestorWire — RAILGUN, a revolutionary smart contracts protocol and DeFi game-changer, is thrilled to announce an agreement with the prominent Bad Media Group to raise its market visibility and adoption goals. The Bad Media Group, led by crypto-blockchain influencers and hosts of the popular Bad Crypto Podcast (BCP) and The Nifty Show live […]